Abstract
The study aimed to synthesize and evaluate substituted 4-methyl-2-oxo-2H-chromen-7-yl phenylcarbamates as potent acetylcholinesterase (AChE) inhibitors and anti-amnestic agents. The compounds were evaluated for AChE and butyrylcholinesterase (BuChE) inhibitory activity in rat brain homogenate and plasma, respectively. The most potent test compound 4d was evaluated for memory testing in scopolamine-induced amnesia. The phenylcarbamate substituted coumarins (4a-4h) demonstrated more potent AChE inhibitory as compared to parent 7-hydroxy-4-methylcoumarin. The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20. The compound 4d displayed the most potent AChE inhibitory activity with IC50 = 13.5 ± 1.7 nM, along with amelioration of amnesia in mice in terms of restoration of time spent in target quadrant and escap latency time. It is concluded that carbamate derivatives of coumarin may be employed as potential AChE inhibitors and anti-amnestic agents.
Keywords: Phenylcarbamates, coumarin, Alzheimer’s disease, acetylcholinesterase inhibitors.
Medicinal Chemistry
Title:Synthesis and Evaluation of Substituted 4-methyl-2-oxo-2H-chromen-7-yl Phenyl Carbamates as Potent Acetylcholinesterase Inhibitors and Anti- Amnestic Agents
Volume: 9 Issue: 5
Author(s): Preet Anand and Baldev Singh
Affiliation:
Keywords: Phenylcarbamates, coumarin, Alzheimer’s disease, acetylcholinesterase inhibitors.
Abstract: The study aimed to synthesize and evaluate substituted 4-methyl-2-oxo-2H-chromen-7-yl phenylcarbamates as potent acetylcholinesterase (AChE) inhibitors and anti-amnestic agents. The compounds were evaluated for AChE and butyrylcholinesterase (BuChE) inhibitory activity in rat brain homogenate and plasma, respectively. The most potent test compound 4d was evaluated for memory testing in scopolamine-induced amnesia. The phenylcarbamate substituted coumarins (4a-4h) demonstrated more potent AChE inhibitory as compared to parent 7-hydroxy-4-methylcoumarin. The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20. The compound 4d displayed the most potent AChE inhibitory activity with IC50 = 13.5 ± 1.7 nM, along with amelioration of amnesia in mice in terms of restoration of time spent in target quadrant and escap latency time. It is concluded that carbamate derivatives of coumarin may be employed as potential AChE inhibitors and anti-amnestic agents.
Export Options
About this article
Cite this article as:
Anand Preet and Singh Baldev, Synthesis and Evaluation of Substituted 4-methyl-2-oxo-2H-chromen-7-yl Phenyl Carbamates as Potent Acetylcholinesterase Inhibitors and Anti- Amnestic Agents, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050009
DOI https://dx.doi.org/10.2174/1573406411309050009 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stress and Angiotensin II: Novel Therapeutic Opportunities
Current Drug Targets - CNS & Neurological Disorders ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research HDL Genetic Defects
Current Pharmaceutical Design The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Anti-Aggressive, Brain Neurotransmitters and Receptor Binding Study of Fumaria indica in Rodents
Current Psychopharmacology Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis
Current Alzheimer Research Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Current Alzheimer Research Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Molecular Imaging in the Default Mode Network
Current Molecular Imaging (Discontinued) Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design A Review of the Clinical, Radiological and Biochemical Characteristics and Genetic Causes of High Bone Mass Disorders
Current Drug Targets